Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+  metastatic breast cancer: an analysis of the SONABRE registry

ConclusionThe prognosis of patients with de novo HER2  + ABC has improved considerably. Since 2013 one in four patients were alive and free from progression on first-given therapy for at least five years.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research